GlaxoSmithKline Pharmaceuticals Limited (BOM: 500660)
India
· Delayed Price · Currency is INR 2,325.25
-9.70 (-0.42%)
At close: Dec 19, 2024
GlaxoSmithKline Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Operating Revenue | 35,605 | 34,537 | 32,517 | 32,780 | 29,256 | 32,244 | Upgrade
|
| Revenue | 35,605 | 34,537 | 32,517 | 32,780 | 29,256 | 32,244 | Upgrade
|
| Revenue Growth (YoY) | 7.62% | 6.21% | -0.80% | 12.05% | -9.27% | 3.08% | Upgrade
|
| Cost of Revenue | 13,844 | 13,552 | 13,041 | 13,782 | 12,824 | 13,250 | Upgrade
|
| Gross Profit | 21,761 | 20,985 | 19,476 | 18,998 | 16,432 | 18,994 | Upgrade
|
| Selling, General & Admin | 7,275 | 7,358 | 7,062 | 7,397 | 6,858 | 7,741 | Upgrade
|
| Other Operating Expenses | 4,210 | 4,541 | 4,272 | 3,931 | 3,594 | 4,560 | Upgrade
|
| Operating Expenses | 12,170 | 12,595 | 11,992 | 12,010 | 11,236 | 13,124 | Upgrade
|
| Operating Income | 9,591 | 8,390 | 7,484 | 6,988 | 5,196 | 5,869 | Upgrade
|
| Interest Expense | -17.29 | -17.99 | -18.12 | -19.96 | -35.31 | -63.36 | Upgrade
|
| Interest & Investment Income | 729.28 | 729.28 | 698.55 | 711.53 | 1,106 | 762.06 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | -99.07 | -51.36 | - | -123.7 | Upgrade
|
| Other Non Operating Income (Expenses) | 55.3 | - | - | 37 | 0.08 | 0 | Upgrade
|
| EBT Excluding Unusual Items | 10,358 | 9,101 | 8,066 | 7,666 | 6,266 | 6,444 | Upgrade
|
| Merger & Restructuring Charges | -1,633 | -1,633 | -113.7 | -200.84 | -2.4 | -591.46 | Upgrade
|
| Gain (Loss) on Sale of Investments | 487.76 | 487.76 | 307.79 | 5.92 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 8.89 | 8.89 | 0.28 | 3.24 | -0.59 | 23.34 | Upgrade
|
| Asset Writedown | - | - | - | 2.61 | -2,090 | -7,041 | Upgrade
|
| Legal Settlements | - | - | - | - | - | -170 | Upgrade
|
| Other Unusual Items | 70.77 | 196.87 | 104.02 | 314 | 366.44 | 4,392 | Upgrade
|
| Pretax Income | 9,293 | 8,162 | 8,364 | 7,790 | 4,540 | 3,058 | Upgrade
|
| Income Tax Expense | 2,542 | 2,262 | 2,288 | 3,983 | 1,667 | 2,125 | Upgrade
|
| Earnings From Continuing Operations | 6,750 | 5,900 | 6,076 | 3,808 | 2,873 | 932.05 | Upgrade
|
| Earnings From Discontinued Operations | - | - | 30.45 | 13,140 | 708.78 | - | Upgrade
|
| Net Income | 6,750 | 5,900 | 6,107 | 16,947 | 3,581 | 932.05 | Upgrade
|
| Net Income to Common | 6,750 | 5,900 | 6,107 | 16,947 | 3,581 | 932.05 | Upgrade
|
| Net Income Growth | 4.21% | -3.39% | -63.97% | 373.19% | 284.26% | -79.07% | Upgrade
|
| Shares Outstanding (Basic) | 169 | 169 | 169 | 169 | 169 | 169 | Upgrade
|
| Shares Outstanding (Diluted) | 169 | 169 | 169 | 169 | 169 | 169 | Upgrade
|
| Shares Change (YoY) | -1.89% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 39.84 | 34.83 | 36.05 | 100.04 | 21.14 | 5.50 | Upgrade
|
| EPS (Diluted) | 39.84 | 34.83 | 36.05 | 100.04 | 21.14 | 5.50 | Upgrade
|
| EPS Growth | 6.22% | -3.39% | -63.97% | 373.19% | 284.26% | -79.07% | Upgrade
|
| Free Cash Flow | 9,401 | 5,508 | 4,402 | 7,761 | 5,337 | 3,346 | Upgrade
|
| Free Cash Flow Per Share | 55.49 | 32.51 | 25.98 | 45.81 | 31.50 | 19.75 | Upgrade
|
| Dividend Per Share | - | 32.000 | 32.000 | 30.000 | 30.000 | 20.000 | Upgrade
|
| Dividend Growth | - | 0% | 6.67% | 0% | 50.00% | 0% | Upgrade
|
| Gross Margin | 61.12% | 60.76% | 59.89% | 57.96% | 56.17% | 58.91% | Upgrade
|
| Operating Margin | 26.94% | 24.29% | 23.02% | 21.32% | 17.76% | 18.20% | Upgrade
|
| Profit Margin | 18.96% | 17.08% | 18.78% | 51.70% | 12.24% | 2.89% | Upgrade
|
| Free Cash Flow Margin | 26.40% | 15.95% | 13.54% | 23.68% | 18.24% | 10.38% | Upgrade
|
| EBITDA | 9,994 | 8,805 | 7,884 | 7,428 | 5,733 | 6,429 | Upgrade
|
| EBITDA Margin | 28.07% | 25.50% | 24.25% | 22.66% | 19.60% | 19.94% | Upgrade
|
| D&A For EBITDA | 403.36 | 415.36 | 399.67 | 439.6 | 537.22 | 559.25 | Upgrade
|
| EBIT | 9,591 | 8,390 | 7,484 | 6,988 | 5,196 | 5,869 | Upgrade
|
| EBIT Margin | 26.94% | 24.29% | 23.02% | 21.32% | 17.76% | 18.20% | Upgrade
|
| Effective Tax Rate | 27.36% | 27.72% | 27.35% | 51.12% | 36.72% | 69.52% | Upgrade
|
| Revenue as Reported | 36,886 | 35,763 | 33,524 | 33,538 | 30,362 | 33,034 | Upgrade
|
| Advertising Expenses | - | 1,094 | 1,091 | 1,277 | 673.72 | 1,382 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.